State Board of Administration of Florida Retirement System Decreases Stock Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Posted by Defense World Staff on May 8th, 2023

State Board of Administration of Florida Retirement System decreased its position in shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) by 8.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 185,054 shares of the company’s stock after selling 17,081 shares during the quarter. State Board of Administration of Florida Retirement System owned approximately 0.14% of Henry Schein worth $14,780,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in HSIC. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Henry Schein by 2.4% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 5,262 shares of the company’s stock worth $459,000 after buying an additional 122 shares during the last quarter. Summit Trail Advisors LLC grew its holdings in shares of Henry Schein by 2.1% during the fourth quarter. Summit Trail Advisors LLC now owns 6,323 shares of the company’s stock worth $505,000 after buying an additional 132 shares during the last quarter. TD Asset Management Inc grew its holdings in shares of Henry Schein by 0.4% during the fourth quarter. TD Asset Management Inc now owns 35,431 shares of the company’s stock worth $2,830,000 after buying an additional 152 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund lifted its position in Henry Schein by 3.4% in the third quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 4,878 shares of the company’s stock valued at $321,000 after purchasing an additional 161 shares during the period. Finally, Wetherby Asset Management Inc. lifted its position in Henry Schein by 1.6% in the first quarter. Wetherby Asset Management Inc. now owns 10,860 shares of the company’s stock valued at $947,000 after purchasing an additional 171 shares during the period. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on HSIC. Morgan Stanley reduced their price objective on shares of Henry Schein from $70.00 to $69.00 and set an “underweight” rating for the company in a research report on Tuesday, February 21st. StockNews.com upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a research report on Saturday, April 8th. Credit Suisse Group reduced their price target on shares of Henry Schein from $99.00 to $97.00 and set an “outperform” rating for the company in a research report on Tuesday, February 28th. Piper Sandler lifted their price target on shares of Henry Schein from $85.00 to $97.00 and gave the company an “overweight” rating in a research report on Monday, February 6th. Finally, UBS Group lifted their price target on shares of Henry Schein from $75.00 to $82.00 and gave the company a “neutral” rating in a research report on Tuesday, March 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $85.89.

Henry Schein Stock Up 0.8 %

HSIC stock opened at $79.75 on Monday. The stock has a market capitalization of $10.46 billion, a P/E ratio of 20.50, a PEG ratio of 1.84 and a beta of 0.82. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.91 and a current ratio of 1.79. Henry Schein, Inc. has a one year low of $64.75 and a one year high of $89.72. The company has a 50 day moving average price of $80.54 and a two-hundred day moving average price of $80.33.

Henry Schein (NASDAQ:HSIC – Get Rating) last released its earnings results on Thursday, February 16th. The company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.21 by $0.14. Henry Schein had a net margin of 4.25% and a return on equity of 15.79%. The firm had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.37 billion. During the same period in the previous year, the company earned $1.07 EPS. Henry Schein’s revenue for the quarter was up 1.2% on a year-over-year basis. As a group, sell-side analysts expect that Henry Schein, Inc. will post 5.32 EPS for the current year.

Insider Activity

In other news, Director Kurt P. Kuehn sold 1,909 shares of the business’s stock in a transaction on Thursday, March 16th. The shares were sold at an average price of $77.46, for a total transaction of $147,871.14. Following the completion of the sale, the director now directly owns 15,675 shares of the company’s stock, valued at approximately $1,214,185.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Kurt P. Kuehn sold 1,909 shares of Henry Schein stock in a transaction on Thursday, March 16th. The shares were sold at an average price of $77.46, for a total transaction of $147,871.14. Following the transaction, the director now owns 15,675 shares in the company, valued at approximately $1,214,185.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Philip A. Laskawy sold 6,405 shares of Henry Schein stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $78.74, for a total transaction of $504,329.70. Following the transaction, the director now owns 26,239 shares in the company, valued at approximately $2,066,058.86. The disclosure for this sale can be found here. Corporate insiders own 1.00% of the company’s stock.

Henry Schein Profile

(Get Rating)

Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins.